Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
Arcturus Therapeutics Holdings Inc. (Arcturur, a messenger RNA medicines company focused on the development of liver and respiratory therapeutics), will release its financial results for the quarter ended September 30, 2026 after the market close on November 5th and will host a conference call and webcast on November 6th. The company was founded in 2013 and is known for developing the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world. Its pipeline includes programs in cystic fibrosis (CF), ornithine transcarbamylase (OTC) deficiency, phenylketonuria (PKU) and Gout. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the US., Europe, Japan, China, and other countries).
公開済み : 11時間前 沿って の Business Health
SAN DIEGO--(BUSINESS WIRE)--$ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and res... [1874 symbols]
